PetIQ Inc (NASDAQ:PETQ) – Analysts at Oppenheimer issued their Q1 2019 earnings estimates for shares of PetIQ in a report released on Tuesday, March 12th. Oppenheimer analyst B. Nagel forecasts that the company will post earnings per share of $0.06 for the quarter. Oppenheimer also issued estimates for PetIQ’s Q2 2019 earnings at $0.37 EPS, Q3 2019 earnings at $0.32 EPS, Q4 2019 earnings at $0.10 EPS and FY2020 earnings at $1.24 EPS.

PetIQ (NASDAQ:PETQ) last released its quarterly earnings data on Monday, March 11th. The company reported $0.06 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.01). The company had revenue of $111.02 million for the quarter, compared to analysts’ expectations of $98.72 million. PetIQ had a negative net margin of 0.15% and a positive return on equity of 9.57%.

A number of other equities analysts have also weighed in on PETQ. BidaskClub lowered PetIQ from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 15th. Jefferies Financial Group reiterated a “buy” rating and set a $39.00 price objective on shares of PetIQ in a research note on Tuesday, January 15th. ValuEngine upgraded PetIQ from a “hold” rating to a “buy” rating in a research note on Wednesday, February 13th. Raymond James reduced their price objective on PetIQ from $42.00 to $39.00 and set an “outperform” rating for the company in a research note on Monday, March 4th. Finally, Zacks Investment Research lowered PetIQ from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 5th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. PetIQ has a consensus rating of “Buy” and a consensus target price of $40.83.

NASDAQ PETQ opened at $27.22 on Friday. The stock has a market cap of $781.15 million, a price-to-earnings ratio of 21.78, a P/E/G ratio of 1.23 and a beta of 2.27. PetIQ has a fifty-two week low of $17.56 and a fifty-two week high of $43.93. The company has a quick ratio of 1.10, a current ratio of 2.51 and a debt-to-equity ratio of 0.49.

In related news, insider Will Santana sold 10,600 shares of PetIQ stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $23.53, for a total value of $249,418.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO John Newland sold 5,500 shares of PetIQ stock in a transaction dated Wednesday, January 16th. The shares were sold at an average price of $29.00, for a total value of $159,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 145,500 shares of company stock valued at $3,987,134. 45.26% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can increased its stake in shares of PetIQ by 2,007.8% in the 4th quarter. Bank of Montreal Can now owns 1,623 shares of the company’s stock valued at $38,000 after purchasing an additional 1,546 shares in the last quarter. Citigroup Inc. increased its stake in shares of PetIQ by 43.5% in the 4th quarter. Citigroup Inc. now owns 1,827 shares of the company’s stock valued at $43,000 after purchasing an additional 554 shares in the last quarter. Rehmann Capital Advisory Group purchased a new position in shares of PetIQ in the 3rd quarter valued at about $55,000. Legal & General Group Plc increased its stake in shares of PetIQ by 42.6% in the 4th quarter. Legal & General Group Plc now owns 2,451 shares of the company’s stock valued at $58,000 after purchasing an additional 732 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of PetIQ by 558.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,647 shares of the company’s stock valued at $133,000 after purchasing an additional 4,790 shares in the last quarter. Hedge funds and other institutional investors own 84.42% of the company’s stock.

About PetIQ

PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

Featured Story: Return on Investment (ROI) Defined, Explained

Earnings History and Estimates for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.